Evidence map›Paper›PMID 31037472›Full record

ReviewGeroScience2019

Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research.

Anna Csiszar, Priya Balasubramanian, Stefano Tarantini, Andriy Yabluchanskiy, Xin A Zhang, Zsolt Springo, Doris Benbrook, William E Sonntag, Zoltan Ungvari

Open access · bronzeAbstract readReview
In one paragraph

Review in GeroScience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Anna CsiszarDepartment of Geriatric Medicine Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Priya BalasubramanianDepartment of Geriatric Medicine Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Stefano TarantiniDepartment of Geriatric Medicine Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Andriy YabluchanskiyDepartment of Geriatric Medicine Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Xin A ZhangDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Zsolt SpringoDepartment of Geriatric Medicine Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Doris BenbrookStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
William E SonntagDepartment of Geriatric Medicine Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA.
Zoltan UngvariDepartment of Geriatric Medicine Vascular Cognitive Impairment and Neurodegeneration Program, Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, 975 NE 10th Street, BRC 1311, Oklahoma City, OK, 73104, USA. zoltan-ungvari@ouhsc.edu.ORCID 0000-0002-6035-6039
University of Oklahoma Health Sciences Center · USSemmelweis University · HUUniversity of Szeged · HU

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TIMOTHY M VANWAGONER · 2013 to 2026
$68.2M
Visualizing insulin actions on neuronal metabolism and function using fluorescent biosensorsP20GM125528 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Veronica Galvan, William Edmund Sonntag · 2019 to 2026
$17.8M
Targeted DNA Methylation and Mitochondrial Heteroplasmy CoreP30AG050911 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI William Edmund Sonntag · 2015 to 2026
$13.9M
GEROSCIENCE TRAINING PROGRAM IN OKLAHOMAT32AG052363 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Benjamin Francis Miller, William Edmund Sonntag · 2017 to 2026
$3.6M
Effects of Radiation on Brain Microvasculature and CognitionR01NS056218 · NINDS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA, SONNTAG, WILLIAM EDMUND · 2007 to 2018
$3.6M
Ovarian Cancer ChemopreventionR01CA196200 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BENBROOK, DORIS MANGIARACINA · 2015 to 2019
$2.5M
NOVEL APPROACHES FOR REGULATION OF IGF-1 LEVELS THROUGHOUT THE LIFESPANR01AG038747 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI SONNTAG, WILLIAM EDMUND · 2011 to 2015
$2.4M
Cerebral microhemorrhages and gait dysfunction in agingR01AG055395 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA · 2017 to 2025
$2.3M
Targeting HPV Consequences in a Cervical Cancer Clinical TrialR01CA200126 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BENBROOK, DORIS MANGIARACINA, MOORE, KATHLEEN N. · 2016 to 2021
$2.1M
Radiation-induced astrocyte dysfunction and cognitive declineR01NS100782 · NINDS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI UNGVARI, ZOLTAN ISTVAN · 2018 to 2022
$1.7M
Microvascular mechanisms of neuroinflammation: role of Nrf2R01AG047879 · NIA · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CSISZAR, ANNA · 2014 to 2018
$1.5M
Tetraspanin-enriched microdomains and endothelial barrier functionR01HL132553 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ZHANG, XIN A · 2017 to 2020
$1.5M
National Cancer Institute (US) R01-CA196200National Cancer Institute (US) R01-CA200126National Institute of General Medical Sciences (US) U54GM104938National Institute on Aging (US) R01-AG047879National Institute on Aging (US) R01-AG055395NCI NIH HHS R01 CA196200NCI NIH HHS R01 CA200126NCI NIH HHS R03 CA099197NHLBI NIH HHS R01 HL132553NIA NIH HHS P30 AG050911NIA NIH HHS R01 AG038747NIA NIH HHS R01 AG047879NIA NIH HHS R01 AG055395NIA NIH HHS T32 AG052363NIGMS NIH HHS P20 GM125528NIGMS NIH HHS U54 GM104938NINDS NIH HHS R01 NS056218NINDS NIH HHS R01-NS056218NINDS NIH HHS R01 NS100782NINDS NIH HHS R01-NS100782
6 · The paper itself

Abstract

There is significant overlap between the cellular and molecular mechanisms of aging and pathways contributing to carcinogenesis, including the role of genome maintenance pathways. In the field of geroscience analysis of novel genetic mouse models with either a shortened, or an extended, lifespan provides a unique opportunity to evaluate the synergistic roles of longevity assurance pathways in cancer resistance and regulation of lifespan and to develop novel targets for interventions that both delay aging and prevent carcinogenesis. There is a growing need for robust assays to assess the susceptibility of cancer in these models. The present review focuses on a well-characterized method frequently used in cancer research, which can be adapted to study resilience to genotoxic stress and susceptibility to genotoxic stress-induced carcinogenesis in geroscience research namely, chemical carcinogenesis induced by treatment with 7,12-dimethylbenz(a)anthracene (DMBA). Recent progress in understanding how longer-living mice may achieve resistance to chemical carcinogenesis and how these pathways are modulated by anti-aging interventions is reviewed. Strain-specific differences in sensitivity to DMBA-induced carcinogenesis are also explored and contrasted with mouse lifespan. The clinical relevance of inhibition of DMBA-induced carcinogenesis for the pathogenesis of mammary adenocarcinomas in older human subjects is discussed. Finally, the potential role of insulin-like growth factor-1 (IGF-1) in the regulation of pathways responsible for cellular resilience to DMBA-induced mutagenesis is discussed.

Indexed as

DNA Damage9,10-Dimethyl-1,2-benzanthraceneAgingAnimalsCarcinogenesisDisease Models, AnimalFemaleGeriatricsHumansLongevityMaleMammary Neoplasms, ExperimentalMiceRats, Sprague-DawleyResearchRodentia9,10-Dimethyl-1,2-benzanthraceneCancerCarcinomaDNA repairHealth spanMutagenesisMutationTumor

Identifiers

PMID31037472
PMCPMC6544731
OpenAlexW2943690909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.